Traws Pharma (NASDAQ:TRAW – Get Free Report) and Orion OYJ (OTCMKTS:ORINY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Profitability
This table compares Traws Pharma and Orion OYJ’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Traws Pharma | N/A | -23,868.92% | -171.09% |
| Orion OYJ | 30.25% | 54.09% | 33.33% |
Analyst Ratings
This is a breakdown of recent ratings for Traws Pharma and Orion OYJ, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Traws Pharma | 1 | 4 | 0 | 0 | 1.80 |
| Orion OYJ | 0 | 1 | 0 | 1 | 3.00 |
Traws Pharma presently has a consensus price target of $1.00, suggesting a potential upside of 471.43%. Given Traws Pharma’s higher possible upside, research analysts clearly believe Traws Pharma is more favorable than Orion OYJ.
Earnings & Valuation
This table compares Traws Pharma and Orion OYJ”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Traws Pharma | $2.79 million | 0.96 | $9.17 million | ($1.58) | -0.11 |
| Orion OYJ | $2.14 billion | 7.42 | $566.04 million | $2.71 | 20.72 |
Orion OYJ has higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
8.0% of Traws Pharma shares are held by institutional investors. 8.7% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Traws Pharma has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Orion OYJ has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
Summary
Orion OYJ beats Traws Pharma on 10 of the 14 factors compared between the two stocks.
About Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
About Orion OYJ
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
